ATE443768T1 - Impfstoff gegen staphylokokken-vergiftung - Google Patents

Impfstoff gegen staphylokokken-vergiftung

Info

Publication number
ATE443768T1
ATE443768T1 AT99943610T AT99943610T ATE443768T1 AT E443768 T1 ATE443768 T1 AT E443768T1 AT 99943610 T AT99943610 T AT 99943610T AT 99943610 T AT99943610 T AT 99943610T AT E443768 T1 ATE443768 T1 AT E443768T1
Authority
AT
Austria
Prior art keywords
staphylococco
poisoning
vaccine against
aureus
intoxication
Prior art date
Application number
AT99943610T
Other languages
English (en)
Inventor
John Lee
Peter Pushko
Jonathan Smith
Robert Ulrich
Original Assignee
U S Medical Res Inst Of Infect
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U S Medical Res Inst Of Infect filed Critical U S Medical Res Inst Of Infect
Application granted granted Critical
Publication of ATE443768T1 publication Critical patent/ATE443768T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT99943610T 1998-07-10 1999-07-09 Impfstoff gegen staphylokokken-vergiftung ATE443768T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9241698P 1998-07-10 1998-07-10
PCT/US1999/015569 WO2000002523A2 (en) 1998-07-10 1999-07-09 Vaccine against staphylococcus intoxication

Publications (1)

Publication Number Publication Date
ATE443768T1 true ATE443768T1 (de) 2009-10-15

Family

ID=22233100

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99943610T ATE443768T1 (de) 1998-07-10 1999-07-09 Impfstoff gegen staphylokokken-vergiftung
AT99941953T ATE418612T1 (de) 1998-07-10 1999-07-09 Anthrax-impfstoff

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99941953T ATE418612T1 (de) 1998-07-10 1999-07-09 Anthrax-impfstoff

Country Status (7)

Country Link
US (2) US6632640B1 (de)
EP (2) EP1097213B1 (de)
AT (2) ATE443768T1 (de)
AU (2) AU761021B2 (de)
CA (2) CA2339355A1 (de)
DE (2) DE69940157D1 (de)
WO (2) WO2000002523A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US7087235B2 (en) 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
DE69940157D1 (en) * 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
EP1105154B1 (de) * 1998-08-13 2016-06-01 Walter Reed Army Institute of Research Impfstoffe gegen bakterielle superantigene
EP1171194A1 (de) 1999-04-16 2002-01-16 JOHNSON & JOHNSON CONSUMER COMPANIES, INC. Vorrichtung zur verabreichung von medikamenten mit einem zweikammerbehälter
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
GB0016702D0 (en) 2000-07-08 2000-08-23 Secr Defence Brit Expression system
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0118009D0 (en) * 2001-07-24 2001-09-19 Regma Biotechnologies Ltd Novel preparation
US7045335B2 (en) * 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
US7888490B2 (en) 2001-12-05 2011-02-15 Centre of Biotechnology Jawaharlal Nehru University Process for the preparation of non-toxic anthrax vaccine
US20040082530A1 (en) * 2002-04-11 2004-04-29 Schmaljohn Connie S. Nucleic acid immunization
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
AU2003278776A1 (en) * 2002-09-10 2004-04-30 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
EP1585812B1 (de) 2002-12-13 2017-01-18 Alphavax, Inc. Multiantigene alphavirusrepliconpartikel und verfahren
KR101518309B1 (ko) * 2003-03-20 2015-05-08 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
WO2005034841A2 (en) * 2003-05-14 2005-04-21 Merck & Co., Inc. Anthrax vaccine
EP1651666B1 (de) * 2003-07-11 2009-05-27 Alphavax, Inc. Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
WO2005026203A2 (en) 2003-09-18 2005-03-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna promoters and anthrax vaccines
ES2422171T3 (es) 2004-02-11 2013-09-09 Ligocyte Pharmaceuticals Inc Antígenos de carbunco y procedimientos de uso
EP2298340B1 (de) 2004-09-22 2014-04-16 GlaxoSmithKline Biologicals S.A. Immunogene Zusammensetzung zur Verwendung zur Impfung gegen Staphylokokken
KR20080052509A (ko) * 2005-04-11 2008-06-11 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션 유행성 독감 바이러스에 대한 백신
EA014739B1 (ru) 2005-09-09 2011-02-28 Лабофарм Инк. Композиция тразодона для введения один раз в день
RU2008113439A (ru) 2005-09-09 2009-10-20 Лабофарм Инк. (CA) Композиции с замедленным высвобождением лекарственного средства
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
US20070248960A1 (en) * 2006-04-19 2007-10-25 Rees Dianne M Arrays containing cleavable RNAi molecules
DK2183368T3 (en) 2007-06-21 2016-09-05 Alphavax Inc PROMOTER-FREE CASES FOR EXPRESSION OF ALPHAVIRUS STRUCTURE PROTEINS
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
WO2009063507A1 (en) * 2007-11-12 2009-05-22 Rakesh Bhatnagar Dna vaccine against anthrax
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
EP3281947B1 (de) 2009-04-03 2020-02-12 The University of Chicago Zusammensetzungen und verfahren in verbindung mit protein-a (spa)-varianten
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2555794A4 (de) 2010-04-05 2014-01-15 Univ Chicago Zusammensetzungen und verfahren im zusammenhang mit protein-a-(spa)-antikörpern als immunreaktionsverstärker
ES2655701T3 (es) 2010-07-02 2018-02-21 The University Of Chicago Composiciones y métodos relacionados con variantes de la proteína A (SpA)
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
CA2830415A1 (en) * 2011-03-16 2012-12-13 Regents Of The University Of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US9556281B2 (en) 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
HRP20201127T1 (hr) 2012-04-26 2020-11-27 University Of Chicago Antigeni stafilokokne koagulaze i metode primjene istih
NZ702282A (en) 2012-04-26 2016-07-29 Univ Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
WO2014205111A1 (en) 2013-06-19 2014-12-24 Integrated Biotherapeutics, Inc. Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
EA201891601A1 (ru) 2016-01-10 2019-03-29 Неоткс Терапьютикс Лтд. Способы и композиции, усиливающие эффективность опосредованной суперантигеном иммунотерапии злокачественных опухолей
US11505722B2 (en) * 2017-06-30 2022-11-22 The Boeing Company Nonaqueous sol-gel for adhesion enhancement of water-sensitive materials
US11260120B2 (en) 2017-07-27 2022-03-01 Integrated Biotherapeutic Vaccines, Inc. Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
AU2020273471B2 (en) 2019-05-14 2026-05-07 The University Of Chicago Methods and compositions comprising Staphylococcus protein A (SpA) variants
EA202193121A1 (ru) 2019-05-15 2022-02-21 Неоткс Терапьютикс Лтд. Лечение рака
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections
IL291821A (en) 2019-10-02 2022-06-01 Janssen Vaccines & Prevention Bv Staphylococcus peptides and methods of use
AU2021357520A1 (en) 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU681341B2 (en) * 1992-01-28 1997-08-28 National Jewish Center For Immunology And Respiratory Medicine Protective effects of mutated superantigens
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0711829A3 (de) * 1993-09-15 1997-07-09 Viagene Inc Rekombinanter Alphavirus Vektor
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
GB9604045D0 (en) * 1996-02-26 1996-04-24 Smithkline Beecham Plc Novel compounds
GB9618107D0 (en) * 1996-08-30 1996-10-09 Secr Defence Vaccine production
US6075119A (en) * 1997-04-07 2000-06-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
US6713284B2 (en) * 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
EP1055429A4 (de) * 1998-02-15 2004-09-08 Juridical Foundation Neue vorbeugungsmedizin/heilmittel für immunopathien
WO2000000616A2 (en) * 1998-06-29 2000-01-06 U.S. Medical Research Institute Of Infectious Diseases Marburg virus vaccines
DE69940157D1 (en) * 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
EP1105154B1 (de) * 1998-08-13 2016-06-01 Walter Reed Army Institute of Research Impfstoffe gegen bakterielle superantigene
AU771774B2 (en) * 1998-12-07 2004-04-01 U.S. Medical Research Institute Of Infectious Diseases Live attenuated Venezuelan equine encephalitis vaccine

Also Published As

Publication number Publication date
ATE418612T1 (de) 2009-01-15
EP1097213A2 (de) 2001-05-09
EP1097212B1 (de) 2008-12-24
WO2000002522A2 (en) 2000-01-20
WO2000002523A2 (en) 2000-01-20
AU5542699A (en) 2000-02-01
CA2337966A1 (en) 2000-01-20
WO2000002522A3 (en) 2000-10-12
CA2339355A1 (en) 2000-01-20
US6632640B1 (en) 2003-10-14
WO2000002523A3 (en) 2000-11-23
US7374931B2 (en) 2008-05-20
WO2000002523A9 (en) 2000-07-27
DE69940157D1 (en) 2009-02-05
US20040009183A1 (en) 2004-01-15
AU758019B2 (en) 2003-03-13
DE69941454D1 (de) 2009-11-05
AU761021B2 (en) 2003-05-29
AU5667399A (en) 2000-02-01
EP1097212A2 (de) 2001-05-09
WO2000002522A9 (en) 2001-04-05
EP1097213B1 (de) 2009-09-23

Similar Documents

Publication Publication Date Title
DE69941454D1 (de) Impfstoff gegen staphylokokken-vergiftung
TR200806259T2 (tr) Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
WO1999051748A3 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
CY1109531T1 (el) Πρωτεϊνες συντηξης του μυκοβακτηριδιου της φυματιωσης
EA200100565A1 (ru) Новые стрептококковые антигены
DE602004020189D1 (de) Adjuvante influenza-vakzine
ATE376996T1 (de) Antibakterielle mittel
DE60130200D1 (de) 3-cyanochinoline, 3-cyano-1,6-naphthyridine und 3-cyano-1,7-naphthyridine als protein-kinaseinhibitoren
DE602004024542D1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
TR200000115T2 (tr) Tüberkülozun immünoterapi ve teşhisi için bileşikler ve bu bileşiklerin kullanımı için yöntemler.
ATE382693T1 (de) Impfstoffe gegen neurotoxine von clostridium botulinum
CY1106234T1 (el) Συνθεσεις για τη θepαπεια μολυνσεων staphylococcus aureus
DK1625393T3 (da) Vacciner, som medfører beskyttelse mod infektion af Streptococcus pneumonia
TW200619228A (en) Immunogenic compositions of staphylococcus epidermidis polypeptide antigens
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof
WO2002011549A3 (en) Treatment of mycobacterial infection
WO2002024223A3 (en) Prevention and treatment of streptococcal and staphylococcal infection
WO2004073603A3 (en) Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity
WO2003096877A3 (en) Prevention and treatment of streptococcal and staphylococcal infection
RU97113193A (ru) Штамм бактерий bacillus anthracis 81/1, используемый в качестве тест-заражающей культуры
ATE426631T1 (de) 1-vinylpyrrolidin-2-on/ester copolymere
UA25233A (uk) Спосіб профілактики сибірки у твариh
AR010517A1 (es) Compuestos y metodos para la inmunoterapia y diagnostico de tuberculosis
AUPR001300A0 (en) Caged animal environment enrichment device

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties